C-2KLQMitoRx Therapeutics
mitochondrial metabolism, small molecule, obesity
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-2KLQ
C-2KLQC-2KLQmitochondrial metabolism, small molecule, obesity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
MitoRx Therapeutics states that mitochondrial dysfunction, driven in part by trans-sulfuration deficiency, is a shared pathophysiology across several progressive rare diseases and broader indications, and that its first-in-class mitochondrial-targeted sulfide donor platform can reverse this dysfunction to arrest disease progression. The company presents its MTRX approach as restoring adaptive metabolism and overcoming mitochondrial-driven disease states associated with muscle weakness, muscle wasting, cognitive deficit, and neurodegeneration through safe, targeted, enzymatic release of sulfide within mitochondria.
SourceMitoRx Therapeutics states that mitochondrial dysfunction is a shared driver of decline in muscular dystrophy, neurodegeneration, and other progressive diseases, and that its first-in-class mitochondrial-targeted therapeutics can reverse this dysfunction and potentially arrest disease progression. The company presents trans-sulfuration dysfunction as a recurring pathological feature across several rare and broader indications, and argues that restoring adaptive mitochondrial metabolism through targeted sulfide-signaling can overcome muscle weakness, muscle wasting, cognitive deficit, and neurodegeneration.
SourceMitoRx Therapeutics states that mitochondrial dysfunction, particularly involving trans-sulfuration deficiency, is a shared driver of progression in rare neuromuscular, metabolic, and neurodegenerative diseases, and that its first-in-class mitochondrial-targeted sulfide donor platform can reverse this dysfunction, restore adaptive metabolism, and potentially arrest disease progression through safe, highly targeted mitochondrial medicine.
Source